CVS Health reported first-quarter results that significantly exceeded Wall Street's expectations, driven by a strong rebound in its insurance business, Aetna, as well as outperformance in its retail pharmacy and health services units [1]. The company posted adjusted earnings per share of $2.57, surpassing the expected $2.20, and revenue of $100.43 billion, beating the anticipated $95.09 billion [1]. Net income for the quarter was $2.94 billion, or $2.30 per share, compared to $1.78 billion, or $1.41 per share, in the same period a year ago [1]. Sales increased 6.2% year-over-year, with all three business segments showing growth [1].
In response to the strong performance, CVS raised its full-year profit guidance to a range of $7.30 to $7.50 per share, up from the previous $7 to $7.20 per share outlook [1]. The company also increased its 2026 revenue forecast to at least $405 billion, up from the prior outlook of at least $400 billion, attributing the majority of the $5 billion increase to positive momentum in the Aetna insurance unit [1]. CFO Brian Newman emphasized that the results reflect continued progress in CVS's turnaround plan, which includes $2 billion in cost cuts, closing underperforming stores, and leadership changes [1].
Shares of CVS rose more than 4% in premarket trading following the announcement, indicating a positive market reaction to the results and guidance raise [1]. Newman noted that while the company is confident in its outlook, it remains cautious due to persistently high medical costs [1]. CVS's performance adds to a generally strong first quarter for the broader health insurance sector [1].
The company highlighted that its strategy of setting realistic targets and then outperforming them has contributed to its recent success, marking the fourth or fifth consecutive quarter of beating and raising guidance [1].
CONCLUSION
CVS Health's strong first-quarter results and raised outlook signal successful execution of its turnaround strategy and renewed strength in its insurance business. The positive earnings surprise and guidance boost drove shares higher, reflecting investor confidence. However, the company remains cautious due to ongoing high medical costs.